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Background: Transgender individuals receive cross-sex hormonal therapy to induce desired
secondary sexual characteristics despite limited data regarding its effects on cardiovascular health.
Methods: A comprehensive search of several databases up to 7 April 2015 was conducted for studies
evaluating the effect of sex steroiduseon lipids,myocardial infarction, stroke, venous thromboembolism
(VTE), and mortality in transgender individuals. Pairs of reviewers selected and appraised the studies. A
random-effects model was used to pool weightedmean differences and 95% confidence intervals (CIs).
Results:We found 29 eligible studies withmoderate risk of bias. In female-to-male (FTM) individuals, sex
steroid therapywasassociatedwith statistically significant increases in serumtriglyceride (TG) levels at 3 to
6months and at$24months (21.4mg/dL; 95%CI: 0.14 to 42.6) and in low-density lipoprotein cholesterol
(LDL-C) levels at 12 months and $24 months (17.8 mg/dL; 95% CI: 3.5 to 32.1). High-density lipoprotein
cholesterol (HDL-C) levelsdecreased significantly acrossall follow-upperiods (highest at$24months,28.5
mg/dL; 95% CI: 213.0 to 23.9). In male-to-female (MTF) individuals, serum TG levels were significantly
higher at $24 months (31.9 mg/dL; 95% CI: 3.9 to 59.9) without any changes in other parameters. Few
myocardial infarction, stroke, VTE, and death events were reported (more frequently inMTF individuals).
Conclusions: Low-quality evidence suggests that sex steroid therapy may increase LDL-C and TG
levels and decrease HDL-C level in FTM individuals, whereas oral estrogens may increase TG levels in
MTF individuals. Data about important patient outcomes remain sparse. (J Clin Endocrinol Metab
102: 3914–3923, 2017)
The prevalence of transgender individuals as reportedin the literature is increasing, with recent estimates of
6.8 per 100,000 males seeking transition to the female
gender [male-to-female (MTF)] and 2.6 per 100,000
females seeking transition to the male gender [female-to-
male (FTM)] (1). To decrease gender dysphoria, many
transgender individuals receive cross-sex hormonal
therapy, which suppresses natal secondary sexual char-
acteristics and induces changes consistent with their
desired gender. For MTF transition, the main compo-
nents of cross-sex hormonal therapy are estrogens,
antiandrogens (cyproterone acetate and spironolactone),
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or gonadotropin-releasing hormone (GnRH) agonists.
For FTM transition, testosterone is the main treatment
(2).
Adverse outcomes of sex steroid therapy in other
settings, such as hormone replacement therapy in post-
menopausal women, oral contraceptive pills in pre-
menopausal women, or testosterone in males with
hypogonadism, have been the subject of multiple studies
(3–6). However, differences in patients’ clinical charac-
teristics and hormonal regimens in these trials do not
allow direct application of their results to transgender
individuals receiving feminizing or masculinizing hor-
mone therapy. To date, no randomized trial has evalu-
ated the safety of any feminizing hormone regimen during
MTF transition. For FTM transition, a small randomized
trial with only a 3-month follow-up was conducted
to assess the effects of estrogen deprivation on bone
metabolism and vascular parameters (7). In 2010, a
systematic review of 16 studies found very low-quality
evidence suggesting that cross-sex hormonal therapy was
associated with unfavorable changes in lipid profiles and
inconclusive data about important patient cardiovascular
outcomes (8). Since the publication of that review, more
studies have become available, justifying a new quanti-
tative synthesis of the evidence to inform discussions
between clinicians and transgender individuals regarding
treatment decisions. To this end, we conducted a sys-
tematic review andmeta-analysis of available evidence on
the effect of sex steroids on lipids and important car-
diovascular outcomes in MTF and FTM transgender
individuals.
Methods
We performed a systematic review and meta-analysis to esti-
mate the effects of sex steroid treatment on (1) lipid profiles, (2)
cardiovascular events, (3) venous thromboembolism (VTE),
and (4) mortality in adolescent and adult transgender in-
dividuals. This report followed a rigorous systematic review
protocol that was developed in collaboration with experts from
the Endocrine Society and that adheres to the PRISMA state-
ment (9).
Eligibility criteria
We included randomized trials, observational studies,
and case series of adolescent and adult transgender individuals
who used sex steroids, regardless of whether they had gender-
confirming surgery or not. Eligible studies exposed MTF
transgender individuals to cross-sex hormone therapy includ-
ing estrogen, antiandrogens (cyproterone acetate and spi-
ronolactone), or GnRH agonists and FTM transgender
individuals to testosterone. We included studies that provided a
pre-post intervention comparison of participants followed up
for at least 3 months and studies that compared transgender
individuals (at least 3 months of therapy) with a control group.
Outcomes of interest included changes in (1) lipid profile [total
cholesterol, low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), and triglyceride (TG)
levels]; (2) cardiovascular events (myocardial infarction, tran-
sient ischemic attack, stroke); (3) VTE events; and (4) mortality.
To avoid selection bias and to ascertain a well-documented
exposure for the pre-post intervention comparison, eligible
studies excluded individuals who had received sex steroids—
even when self-prescribed—before the initiation of the study.
We also excluded studies for which information to determine
eligibility was not available in the manuscript and whose au-
thors did not respond to requests for that information. We
included studies regardless of their publication status, language,
or size. Review articles, commentaries, and letters that did not
contain primary data were excluded.
Study identification
A comprehensive search of several databases from 1980 to 7
April 2015 was conducted. Databases included Ovid MED-
LINE In-Process & Other Non-Indexed Citations, Ovid
MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of
Controlled Trials, and Scopus. An experienced librarian (L.J.P.)
designed the search strategy with input from study investigators
with expertise in conducting systematic reviews (S.M. and
N.S.O.). Controlled vocabulary supplemented with key words
was used to search for studies of outcomes of cross-sex hormone
therapy in transgender individuals. The search strategy is
available in the Supplemental Appendix. We reviewed the
reference lists of narrative reviews and consulted with experts to
identify additional references.
The search results were uploaded into a systematic review
software program (DistillerSR; Ottawa, ON, Canada). Re-
viewers working independently and in duplicate reviewed all
abstracts and titles for inclusion (S.M., N.S.O., and R.R.-G.).
After abstracts were screened and potentially eligible studies
were retrieved, the full-text publications were assessed for eli-
gibility by both reviewers with excellent chance-adjusted inter-
reviewer agreement (k statistic = 0.82). Duplicate studies and
studies with overlapping populations were excluded. Dis-
agreements were resolved by consensus (the two reviewers
discussed the discrepancy and reached a final decision).
Data collection and management
Working independently and in duplicate using a standard-
ized form, reviewers collected the following information from
each eligible study: (1) baseline clinical features: age, weight,
body mass index, and whether MTF or FTM transition; (2)
gender-confirming surgery proportion and definition; (3) pro-
portion of patients with risk factors for cardiovascular events;
(4) type of intervention (medication, dose, route, frequency) and
duration of exposure at outcome assessment; and (5) outcomes
(blood lipid fractions, number of cardiovascular events, VTE
events, and deaths). We also extracted the definition of controls
used in the applicable studies. Disagreements were resolved by
discussion and consensus.
Risk of bias assessment
We used the Newcastle-Ottawa tool to evaluate the risk of
bias in observational studies. This tool evaluates the selection of
study cohorts, the comparability of the study cohorts, and the
ascertainment of exposure and outcomes (10). For randomized
trials, we used the Cochrane Collaboration tool for assessing
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risk of bias (11). Reviewers working independently assessed the
risk of bias of included studies in duplicate. Any disagreements
were resolved by consensus.
Author contact
To reduce reporting bias, we contacted by e-mail corre-
sponding authors (or any other author if we were unable to
reach the corresponding author) of each of the eligible studies in
which clarification or more information was needed to de-
termine eligibility or to complete the analysis. Three out of the
ten contacted authors replied.
Meta-analysis
We conducted a random-effects meta-analysis using the
DerSimonian-Laird random-effects method to pool mean dif-
ferences for continuous outcomes and their associated 95%
confidence intervals (CIs) (12). Longitudinal and cross-sectional
studies were pooled separately. We subtracted the baseline
measurement from the follow-up measurement of serum lipids
when calculating the mean differences. Hence, negative values
indicate a decrease from baseline and positive values indicate an
increase. When comparing values against a control group, we
subtracted the control value from the transgender group value;
hence, a positive value indicates a higher value for the trans-
gender group and a negative value indicates a lower value for the
transgender group. We also planned to estimate the pooled
cumulative incidence of cardiovascular events, thrombotic
events, and deaths; however, varied follow-up durations across
studies and the limited number of events in the included studies
precluded pooling.
Inconsistency was assessed using the I2 statistic, with
values,25% indicative of low inconsistency and values.75%
indicative of high inconsistency not due to chance (13). Open
Meta-Analyst was used for statistical analyses (14).
Subgroups and sensitivity analyses
A priori hypotheses to explore potential causes of hetero-
geneity included possible differences in population age (e.g.,
adolescents vs adults); different treatment regimens (e.g., oral vs
transdermal estrogen, estrogens alone vs combination therapy);
outcome characteristics (e.g., symptomatic vs all events); study
design (e.g., controlled study vs single cohort); and study quality
(e.g., blinded vs open outcome assessment, follow-up duration).
Sensitivity analyses were conducted to explain possible in-
consistencies across study results.
Results
Study identification
A total of 391 potentially eligible articles were iden-
tified through our systematic database search, of which
29 were ultimately eligible (7, 15–42) after exclusion of
studies that represented overlapping populations (43–50).
The study selection process is described in Fig. 1.
Supplemental Table 1 summarizes the characteristics
of the included studies. Twenty-eight were cohort studies,
and one was a randomized trial. Seventeen were before
and after cross-sex hormone therapy studies, and four
studies compared transgender participants with a control
group. Twenty-one studies evaluated lipid fractions. Ten
studies evaluated VTE (10 in MTF individuals and 8 in
FTM individuals). Numbers of studies evaluating mor-
tality, myocardial infarction, and stroke were 4, 3, and 2,
respectively.
Across all studies, 4731 transgender patients were
included. These included 3231 MTF participants (23
studies) and 1500 FTM participants (20 studies). No
study provided information solely on adolescent pop-
ulations. The mean age of the MTF group ranged from
19.3 to 43.7 years, and the mean age of the FTM group
ranged from 21.7 to 37.5 years. MTF treatment regimens
included various doses of oral, transdermal, or in-
tramuscular (IM) estrogens, and some regimens included
cyproterone acetate, GnRH agonists (goserelin, triptor-
elin), spironolactone, or anastrozole. Most FTM trans-
gender individuals used various IM preparations of
testosterone and some transdermal, subcutaneous, or
oral testosterone. Exposure and follow-up ranged from
3 months to 41 years.
Risk of bias
We judged the observational studies to be at moderate
risk of bias on the basis of representativeness of the ex-
posed cohort [most were somewhat representative (clinic
based)] and assessment of outcome (record linkage or
self-report). The included randomized trial had an in-
creased risk of bias because of unclear randomization and
allocation concealment methods, lack of blinding, and
high rate of loss to follow-up (see Supplemental Tables 2
and 3).
Meta-analysis
Serum lipids
In FTM transgender individuals, the meta-analysis
(Table 1) showed a statistically significant increase in
serum TG levels at 3 to 6 months of therapy (9 mg/dL;
95%CI: 2.5 to 15.5mg/dL) and at$24months (21.4mg/
dL; 95% CI: 0.1 to 42.6 mg/dL) compared with baseline.
The serum LDL-C level showed a statistically significant
increase when measured at 12 months (11.3 mg/dL; 95%
CI: 5.5 to 17.1 mg/dL) and $24 months (17.8 mg/dL;
95% CI: 3.5 to 32.1 mg/dL). There was a statistically
significant decrease in serum HDL-C level across all
follow-up periods (highest at $24 months, 28.5 mg/dL;
95% CI:213.0 to23.9 mg/dL). Total serum cholesterol
level changes were not statistically significant at any
time period.
In MTF transgender individuals, the meta-analysis
(Table 2) showed no statistically significant difference
in serum LDL-C, HDL-C, and total cholesterol levels
between baseline and any time periods. The serum TG
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level was significantly higher only at $24 months (31.9
mg/dL; 95% CI: 3.9 to 59.9 mg/dL). Using the cross-
sectional studies that compared lipid values in the
transgender population with those of control groups
(natal males), the LDL-C level was statistically signifi-
cantly lower in the transgender group (220.3 mg/dL;
95% CI:230.7 to210.0 mg/dL; I2 = 0%). There was no
difference in serum TG (23 mg/dL; 95% CI: 212.8 to
58.7 mg/dL; I2 = 63.1%), HDL-C (6.9 mg/dL; 95% CI:
25.1 to 18.8 mg/dL; I2 = 83.3%), or total cholesterol
(210 mg/dL; 95% CI: 232.5 to 12.5 mg/dL; I2 =
74.5%) level.
Important patient outcomes
In the MTF group, 56 VTE events occurred in 1767
patients. Rates in the included studies varied from 0% to
5%. In the FTM group, VTE was reported in only one of
771 individuals. Individual study rates ranged from 0%
to 0.34%. Stroke was reported in eight of 859 MTF
participants and was not reported in any of the 340 FTM
participants. Myocardial infarction was reported in 14 of
1073 MTF transgender individuals and one of 478 FTM
transgender individuals.Mortality was reported in 139 of
1486 MTF participants and in 13 of 651 FTM partici-
pants, with a range in individual studies of 0% to 13%
and 0% to 3%, respectively (Figs. 2 and 3). In the
studies that reported cause of death, there were 23
cardiovascular-related deaths and 26 suicides in MTF
transgender individuals, whereas there was one
cardiovascular-related death and one suicide in FTM
transgender individuals.
Subgroup and sensitivity analyses
We performed a sensitivity analysis that included FTM
transgender individuals who were treated with only IM
testosterone (six studies). The change in serum total cho-
lesterol level became statistically significant with an increase
of 10.2 mg/dL (95% CI: 1.7 to 18.6 mg/dL; I2 = 31.2%) at
Figure 1. Flowchart showing the study selection process.
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12 months. Moreover, there was a statistically significant
increase in serumLDL-C levels (11.9mg/dL; 95%CI: 5.9 to
17.9 mg/dL; I2 = 0%) and a decrease in HDL-C level
(28.1 mg/dL; 95%CI:210.9 to25.3 mg/dL; I2 = 14.6%).
Therewas no significant change in serumTG levels (8.9mg/
dL; 95% CI: 26.3 to 24.1 mg/dL; I2 = 53.7%).
We performed subgroup analyses comparing MTF
transgender individuals treated with oral vs transdermal
estrogens (in the setting of cross-sex hormonal therapy)
with regard to lipid fraction changes across different time
periods. The only significant interaction was observed in
serum TG levels at 3 to 6 months, with the oral group
experiencing an increase of 28.2 mg/dL (95% CI: 0.5 to
55.9 mg/dL; I2 = 0%) vs a decrease of 4.8 mg/dL (95%
CI: 221.2 to 11.6 mg/dL; I2 = 0%) in the transder-
mal group (P = 0.04). Because of inconsistent reporting,
we were unable to conduct the other preplanned
subgroup analyses.
Discussion
We performed a systematic review and meta-analysis to
summarize the effect of sex steroid therapy on lipid levels
and important cardiovascular outcomes in transgender
Table 1. Change in Lipid Profile in FTM Transgender Individuals at Different Periods (Follow-Up to Baseline)
Estimate 95% CI I2 Number of Studies
3–6 Months
TG, mg/dL 9 (2.5 to 15.5) 7.7 4
LDL-C, mg/dL 7.1 (23.2 to 17.3) 0 3
HDL-C, mg/dL 26.5 (211.9 to 21.0) 0 3
TC, mg/dL 10.6 (24.2 to 25.4) 73.6 4
12 Months
TG, mg/dL 14.7 (22.7 to 32.1) 75.4 9
LDL-C, mg/dL 11.3 (5.5 to 17.1) 0 8
HDL-C, mg/dL 28.1 (210.6 to 25.7) 0 8
TC, mg/dL 12.0 (23.7 to 27.8) 88.0 9
‡24 Months
TG, mg/dL 21.4 (0.1 to 42.6) 80.0 3
LDL-C, mg/dL 17.8 (3.5 to 32.1) 84.1 3
HDL-C, mg/dL 28.5 (213.0 to 23.9) 70.7 3
TC, mg/dL 14.6 (25.1 to 34.3) 90.2 3
Abbreviation: TC, total cholesterol.
Table 2. Change in Lipid Profile in MTF Transgender Individuals at Different Periods (Follow-Up to Baseline)
Estimate 95% CI I2 Number of Studies
3–6 Months
TG, mg/dL 3.8 (211.6 to 19.3) 63.5 6
LDL-C, mg/dL 23.1 (211.6 to 5.4) 0 3
HDL-C, mg/dL 1.2 (25.7 to 8.1) 70.0 5
TC, mg/dL 21.1 (29.4 to 7.2) 0 4
12 Months
TG, mg/dL 13.6 (26.4 to 33.6) 89.5 10
LDL-C, mg/dL 25.7 (219.5 to 8.1) 85.1 7
HDL-C, mg/dL 0.3 (24.3 to 5.0) 77.4 8
TC, mg/dL 27.9 (219.9 to 4.1) 82.5 10
‡24 Months
TG, mg/dL 31.9 (3.9 to 59.9) 94.4 6
LDL-C, mg/dL 6.6 (29.7 to 22.9) 83.9 5
HDL-C, mg/dL 0.4 (27.7 to 8.5) 93.5 5
TC, mg/dL 9.5 (25.8 to 24.9) 87.4 6
Abbreviation: TC, total cholesterol.
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individuals. In FTM transgender individuals, sex steroid
therapy was associated with an increase in LDL-C and TG
levels and a decrease in HDL-C level. In MTF transgender
individuals, sex steroid therapy was associated with an
increase in TG level, which was driven by oral estrogen
treatment. Data about important patient outcomes such as
myocardial infarction, stroke, VTE, and mortality were
insufficient to allow anymeaningful assessment, although a
higher incidence of these events was found among MTF
transgender individuals. These results were driven by data
from one center where a large number of MTF transgender
individuals received a fairly high dose of oral estrogens (36).
Therefore, the only identifiable effect of cross-sex hormone
therapy appears to be on lipid fractions, which are surro-
gate outcomes of limited patient importance (51–53). The
quality of evidence is low because of the uncontrolled and
observational nature of the included studies, small number
of events leading to imprecision of estimates, short and
varied duration of follow-up, heterogeneity of treatment
regimens, and inconsistency of results across studies that
was unexplained by subgroup analyses (54).
Limitations and strengths
Incomplete searching and arbitrary study selection
represent potential limitations of systematic reviews.
However, the rigorous and comprehensive nature of our
overlapping search strategies, without language restric-
tions and with a medical librarian’s input, should have
minimized the possibility that we missed studies that
could have substantially changed the inferences we drew
(55). The risk of reporting bias is high, particularly when
the body of evidence is based on small observa-
tional studies. We attempted to decrease the chances of
reporting bias by contacting the authors; however, the
response rate was low (56). Although it would have been
clinically meaningful to evaluate the effects of some
important patient characteristics on cardiovascular risk
(e.g., smoking), we were unable to do so because of in-
sufficient data. These limitations could not be overcome
methodologically; however, our review exhibited im-
portant strengths because we sought to summarize the
totality of the available evidence following a predesigned
protocol, with reproducible judgments about study se-
lection and quality and focused analyses, including
an assessment of the effects of oral estrogen and IM
testosterone therapy.
Implications for practice
Clinicians and transgender individuals need reliable
evidence regarding the potential harm of sex steroid
Figure 2. Rate of events (death, stroke, MI, VTE) in FTM transgender individuals treated with sex steroids. F-Up, follow up; MI, myocardial
infarction.
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therapy to guide their management decisions. This review
highlights the low quality of the available evidence and
the overall uncertainty regarding the safety of cross-sex
hormonal therapy.
Our findings suggest that in FTM transgender in-
dividuals, masculinizing hormone therapy (testosterone
based) is associated with significant increases in LDL-C
and TG levels and a decrease in HDL-C level. On the
other hand, in MTF transgender individuals, feminizing
hormone therapy (estrogen based) was associated with a
statistically significant increase in TG levels; further
analysis showed that the TG increase was seen with oral
estrogen therapy in contrast to transdermal estrogen
therapy, which led to a decrease in TG levels. Similar
findings were reported in a previous systematic review
(8). The magnitude of the observed decline in HDL-C
level may appreciably increase the risk of cardiovascular
events (57, 58), whereas the clinical effect of the observed
changes in LDL-C and TG levels may be less (58–60).
Nonetheless, because the lipid profile is a surrogate
marker for overall cardiovascular health, the effect of
these findings on important patient outcomes such as
myocardial infarction and stroke during long-term
therapy remains uncertain.
The effect of sex steroid use has been studied exten-
sively in different patient populations, providing indirect
evidence for clinical care of transgender individuals.
Testosterone use in postmenopausal women has been
associated with a reduction in total cholesterol, HDL-C,
and TG levels and an increase in LDL-C level. However,
in addition to the fact that higher doses are used in FTM
transition, long-term safety data are sparse, and the
quality of the evidence is low (61). A recent meta-analysis
of 35 randomized trials that included older men found a
significant cardiovascular risk in participants using oral
testosterone, whereas neither IM nor transdermal tes-
tosterone significantly changed cardiovascular risk (62).
Uncertainty remains regarding the applicability of these
studies to the care of FTM transgender individuals.
A systematic review of studies including healthy men
did not find an association of endogenous estrogen level
with incident cardiovascular disease, including myocar-
dial infarction, stroke, or death from coronary heart
disease (63). In the Coronary Drug Program, 5 mg of
conjugated estrogen therapy in men 30 to 64 years of age
with a history of myocardial infarction was associated
with increased cardiovascular mortality, whereas 2.5 mg
was associated with a trend toward increased risk of VTE
Figure 3. Rate of events (death, stroke, MI, VTE) in MTF transgender individuals treated with sex steroids. F-Up, follow up; MI, myocardial
infarction.
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(4). A recent Cochrane Database systematic review found
that estrogen hormone therapy in postmenopausal women
conferred no protective effect for all-cause mortality or
myocardial infarction but increased the risk of stroke and
VTE events (64). Observational evidence warranting low
confidence in the estimates suggests that compared with
transdermal estrogen, oral estrogen may be associated
with increased risk of VTE but not myocardial infarction
(65). Although it is unclear how applicable these results
are to the care of MTF transgender individuals, the in-
creased prevalence of cardiovascular disease in the MTF
transgender population raises concern about the extent to
which estrogen preparations can cause harmful events; if
so, modifications of cross-sex hormone therapy may be
necessary.
Clinicians prescribing cross-sex hormonal therapy
need to share with transgender individuals the cur-
rent uncertainty regarding potential side effects of
masculinizing/feminizing hormone therapy and make
treatment decisions based on patients’ values, prefer-
ences, and context (54, 66).
Implications for research
We have identified important knowledge gaps re-
garding the effects of cross-sex hormone therapy on
cardiovascular outcomes. First, there is a paucity of data
regarding myocardial infarction, stroke, or VTE events
and mortality in this population, and the studies evalu-
ating lipid changes have had short follow-up times.
Second, literature addressing this clinical question in the
pediatric/adolescent population is completely lacking.
Research is needed to ascertain the safety of hormonal
therapies in transgender individuals. Conducting re-
search with low risk of bias can be challenging because of
multiple barriers to health care in this population (e.g.,
underreporting of side effects, high rate of loss to follow-
up). However, it is possible to conduct randomized trials
nested within study center cohorts to test the relative
safety of different cross-sex hormone regimens. More-
over, medical centers that provide care to transgender
individuals should make it a priority to conduct long-
term follow-up studies evaluating important patient
outcomes (67). In this context, observational studies in
which baseline cardiovascular risk is assessed and bal-
anced between study groups, with proper ascertainment
of exposure and outcome measures, are feasible and
urgently needed.
Conclusion
Low-quality evidence due to methodological limitations
of included studies, imprecision, and heterogeneity sug-
gests that sex steroid therapy may increase LDL-C and
TG levels and decrease HDL-C levels in FTM transgender
individuals, whereas oral estrogen may increase TG level
in MTF transgender individuals. Data about important
patient outcomes, such as myocardial infarction, stroke,
VTE, and mortality, remain sparse.
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